Janssen Search
Search results
RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
Mar 18, 2024 Czech Repubic Featured data include new results from the Phase 3 MARIPOSA study, which has received U.S. FDA Priority Review, and the Phase 1b PALOMA study of subcutaneous amivantamab PRAGUE, CZECH REPUBLIC (March 18, 2024)-- Johnson & ...
We Need a 'Surge' in RSV Awareness
We Need a 'Surge' in RSV Awareness COVID-19 has been an ever-present part of our lives since 2020 and has altered nearly all the ways in which we interact with the world and with one another. The pandemic has also led to an overall increase in ...
Cracking the Code: How New Clues in Our Blood Could Sharpen Our Understanding of Diseases and Impact How We Treat Them
Cracking the Code: How New Clues in Our Blood Could Sharpen Our Understanding of Diseases and Impact How We Treat Them Nearly 20 years ago, scientific leaders in the United Kingdom began an ambitious endeavor: to create UK Biobank, a uniquely powerful ...
Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
Jan 18, 2023 The Netherlands Independent, scheduled review of Phase 3 Mosaico study finds investigational vaccine regimen lacks efficacy in preventing HIV No vaccine-related safety issues identified LEIDEN, THE NETHERLANDS, (January 18, 2023) – The ...
Our Commitment to Rheumatology
About Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic, symmetric, inflammatory disease involving the synovial joints, where bone and cartilage erosion lead to irreversible joint damage. 1 Despite advancements in treatments, 20 to 30 percent of ...
Increasing Sustainable Access to Medicines
Increasing Sustainable Access to Medicines Janssen, as part of its commitment to Global Public Health, cultivates and helps implement innovative pricing and results-based financing models that improve access to our medicines for patients in resource ...
Janssen Oncology Strengthens Disease Interception Focus with TARIS’ Unique Delivery System
Janssen Oncology Strengthens Disease Interception Focus with TARIS' Unique Delivery System Aug 14, 2020 A small pretzel-shaped device designed as a novel approach for the treatment of bladder cancer attracted Janssen Oncology to TARIS Biomedical in ...
Profiles in Scientific Courage: The First Cancer Cures
Profiles in Scientific Courage: The First Cancer Cures It Takes More Than Just Science During this pandemic year, our sense of urgency in the biomedical research community has been sharpened and tested. In oncology research, I believe that this is a time ...
Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
Feb 07, 2024 United States Data from FRONTIER 1, a Phase 2b clinical trial, show JNJ-2113, the first and only targeted oral peptide that selectively blocks the IL-23 receptor, achieved the primary and all secondary endpoints including PASI a 100 and IGA b ...
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Apr 06, 2024 United States Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 ...